BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and for the alleviation of symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX03, a molecular iodine tablet, which is in pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia; and BPX01, a topical antibiotic gel that is in Phase IIb clinical trial for the treatment of acne vulgaris. The company is also developing BPX02, an injectable product for aesthetic dermatology applications. It serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. The company has collaboration and licensing agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. BioPharmX Corporation is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:BPMX
CUSIPN/A
Phone+1-650-8895020
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-20,633.33%
Return on EquityN/A
Return on Assets-387.79%
Miscellaneous
EmployeesN/A
Outstanding Shares191,520,000
Market Cap$45.42
Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions
What is Biopharmx's stock symbol?
Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."
How were Biopharmx's earnings last quarter?
Biopharmx Corp (NYSEAMERICAN:BPMX) issued its earnings results on Thursday, June, 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The biotechnology company earned $0.02 million during the quarter, compared to analysts' expectations of $0.02 million. View Biopharmx's Earnings History.
When is Biopharmx's next earnings date?
What price target have analysts set for BPMX?
2 analysts have issued twelve-month price targets for Biopharmx's stock. Their predictions range from $1.50 to $3.00. On average, they expect Biopharmx's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 853.4% from the stock's current price. View Analyst Ratings for Biopharmx.
What is the consensus analysts' recommendation for Biopharmx?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Biopharmx?
Biopharmx saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 11,571,519 shares, an increase of 1.7% from the June 15th total of 11,382,040 shares. Based on an average daily trading volume, of 3,201,897 shares, the short-interest ratio is currently 3.6 days. Approximately 6.8% of the shares of the stock are short sold. View Biopharmx's Current Options Chain.
Who are some of Biopharmx's key competitors?
Some companies that are related to Biopharmx include Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford Biodynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP), Medicure Inc. Common Stock (MPH), Oncolytics Biotech (ONC), Kitrinor Metals (SCYB), Emblem (EMMBF) and Pfenex (PFNX).
Who are Biopharmx's key executives?
Biopharmx's management team includes the folowing people:
- Ms. Anja B. Krammer, Co-Founder, Pres & Director (Age 50)
- Mr. Greg Kitchener, Exec. VP & CFO (Age 47)
- Dr. Kin Foong Chan Ph.D., Exec. VP of Research & Technology (Age 44)
- Ms. Marie-Louise Bots, Sr. VP of Corp. Devel.
- Dr. G. Scott Herron, Medical Director
Has Biopharmx been receiving favorable news coverage?
News articles about BPMX stock have been trending somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Biopharmx earned a daily sentiment score of 0.04 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Biopharmx?
Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biopharmx's stock price today?
One share of BPMX stock can currently be purchased for approximately $0.2360.
How big of a company is Biopharmx?
Biopharmx has a market capitalization of $45.42 million.
How can I contact Biopharmx?
Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.
MarketBeat Community Rating for Biopharmx (NYSEAMERICAN BPMX)
MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote "Outperform" if you believe BPMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
